EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction–associated steatohepatitis

Ikki Sakuma, Rafael C Gaspar, Ali R Nasiri, Sylvie Dufour iD, Mario Kahn, Jie Zheng, Traci E LaMoia iD, Mateus T Guerra iD, Yuki Taki, Yusuke Kawashima, Dean Yimlamai iD, Mark Perelis und 9 weitere

Proceedings of the National Academy of Sciences · 06.05.2025 · 122 (18)

DOI: 10.1073/pnas.2502978122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025-05. Verfasst von Ikki Sakuma und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06520. Hauptthemen laut MEDLINE: Cholesterol, Liver, Lipid Droplets, Fatty Liver. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Manpei Suzuki Diabetes Foundation, NIDDK NIH HHS, HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction–associated steatohepatitis (MASH) represents a progressive form of steatotic liver disease which increases the risk for fibrosis and advanced liver disease. The accumulation of discrete species of bioactive lipids has been postulated to activate signaling pathways that promote inflammation and fibrosis. However, the key pathogenic lipid species is a matter of debate. We explored candidates using various dietary, molecular, and genetic models. Mice fed a choline-deficient L-amino acid–defined high-fat diet (CDAHFD) developed steatohepatitis and manifested early markers of liver fibrosis associated with increased cholesterol content in liver lipid droplets within 5 d without any changes in total liver cholesterol content. Treating mice with antisense oligonucleotides against Coenzyme A synthase ( Coasy ) or treatment with bempedoic acid or atorvastatin decreased liver lipid droplet cholesterol content and prevented CDAHFD-induced MASH and the fibrotic response. All these salutary effects were abrogated with dietary cholesterol supplementation. Analysis of human liver samples demonstrated that cholesterol in liver lipid droplets was increased in humans with MASH and liver fibrosis and was higher in PNPLA3 I148M (variants rs738409) than in HSD17B13 variants (rs72613567). Together, these data identify cholesterol in liver lipid droplets as a critical mediator of MASH and demonstrate that Coenzyme A synthase knockdown and bempedoic acid are therapeutic approaches to reduce liver lipid droplet cholesterol content and thereby prevent the development of MASH and liver fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholesterolLiverLipid DropletsFatty LiverAnimalsHumansMiceMaleDiet, High-FatLiver CirrhosisMice, Inbred C57BLNon-alcoholic Fatty Liver DiseaseLipid Metabolism

Stichwörter der Autor:innen

Coenzyme A synthasecholesterollipid dropletmetabolic dysfunction–associated steatohepatitis (MASH)phosphatidylcholine

Substanzen

Cholesterol

Autor:innen und Institutionen

  • Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06520.
  • Department of Molecular Diagnosis, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.
  • Department of Applied Genomics, Kazusa deoxyribonucleic acid Research Institute, Chiba 292-0818, Japan.
  • Department of Pediatrics, Yale School of Medicine, New Haven, CT 06520.
  • Ionis Pharmaceuticals, Carlsbad, CA 92010.
  • Institute for Clinical Diabetology, German Diabetes Center (Deutsches Diabetes-Zentrum), Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf 40225, Germany.

ORCID-Profile: Sylvie Dufour, Traci E LaMoia, Mateus T Guerra, Dean Yimlamai, Daniel F Vatner, Kitt Falk Petersen, Tomoaki Tanaka, Gerald I Shulman

Förderung

  • Manpei Suzuki Diabetes Foundation
  • NIDDK NIH HHS
  • HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • NIGMS NIH HHS

Zitieren

APA

Sakuma, I., Gaspar, R. C., Nasiri, A. R., Dufour, S., Kahn, M., Zheng, J., LaMoia, T. E., Guerra, M. T., Taki, Y., Kawashima, Y., Yimlamai, D., Perelis, M., Vatner, D. F., Petersen, K. F., Huttasch, M., Knebel, B., Kahl, S., Roden, M., Samuel, V. T., …, & Shulman, G. I. (2025). Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction–associated steatohepatitis. Proceedings of the National Academy of Sciences, 122(18). https://doi.org/10.1073/pnas.2502978122

Vancouver

Sakuma I, Gaspar RC, Nasiri AR, Dufour S, Kahn M, Zheng J, et al. Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction–associated steatohepatitis. Proceedings of the National Academy of Sciences. 2025;122(18). doi:10.1073/pnas.2502978122

BibTeX
@article{Sakuma2025,
  author = {Sakuma, Ikki and Gaspar, Rafael C and Nasiri, Ali R and Dufour, Sylvie and Kahn, Mario and Zheng, Jie and LaMoia, Traci E and Guerra, Mateus T and Taki, Yuki and Kawashima, Yusuke and Yimlamai, Dean and Perelis, Mark and Vatner, Daniel F and Petersen, Kitt Falk and Huttasch, Maximilian and Knebel, Birgit and Kahl, Sabine and Roden, Michael and Samuel, Varman T and Tanaka, Tomoaki and Shulman, Gerald I},
  title = {Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction–associated steatohepatitis},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  volume = {122},
  number = {18},
  doi = {10.1073/pnas.2502978122}
}
Kostenlos starten →